HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
IGF1R | Insulin-like growth factor 1 receptor | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
IMPDH1 | IMP (inosine 5'-monophosphate) dehydrogenase 1 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
IMPDH2 | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
JAK1 | Janus kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
JAK2 | Janus kinase 2 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
KIT | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
LCK | LCK proto-oncogene, Src family tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
LIPF | Lipase, gastric | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
LPL | Lipoprotein lipase | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Group enriched |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAOB | Monoamine oxidase B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK11 | Mitogen-activated protein kinase 11 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
METAP2 | Methionyl aminopeptidase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MMP1 | Matrix metallopeptidase 1 (interstitial collagenase) | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MMP11 | Matrix metallopeptidase 11 (stromelysin 3) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Group enriched |
MMP12 | Matrix metallopeptidase 12 (macrophage elastase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
MMP13 | Matrix metallopeptidase 13 (collagenase 3) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
MMP14 | Matrix metallopeptidase 14 (membrane-inserted) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
MMP16 | Matrix metallopeptidase 16 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MMP17 | Matrix metallopeptidase 17 (membrane-inserted) | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MMP19 | Matrix metallopeptidase 19 | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
MMP2 | Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
MMP20 | Matrix metallopeptidase 20 | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Not detected |
MMP21 | Matrix metallopeptidase 21 | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
MMP23B | Matrix metallopeptidase 23B | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
MMP24 | Matrix metallopeptidase 24 (membrane-inserted) | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
MMP25 | Matrix metallopeptidase 25 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MMP26 | Matrix metallopeptidase 26 | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MMP27 | Matrix metallopeptidase 27 | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
MMP28 | Matrix metallopeptidase 28 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Mixed |
MMP3 | Matrix metallopeptidase 3 (stromelysin 1, progelatinase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Group enriched |
MMP7 | Matrix metallopeptidase 7 (matrilysin, uterine) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MMP8 | Matrix metallopeptidase 8 (neutrophil collagenase) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |